Immune Regulation News Volume 13.14 | Apr 23 2021

    0
    114






    IRN 13.14 | Apr 23 2021


    Immune Regulation News by STEMCELL Technologies
    Vol. 13.14 – 23 April, 2021
    TOP STORY

    The CD94/NKG2A Inhibitory Receptor Educates Uterine NK Cells to Optimize Pregnancy Outcomes in Humans and Mice

    Researchers showed that NKG2A genetic ablation in dams mated with wild-type males caused suboptimal maternal vascular responses in pregnancy, accompanied by perturbed placental gene expression, reduced fetal weight, greater rates of smaller fetuses with asymmetric growth, and abnormal brain development.
    [Immunity]

    AbstractGraphical Abstract

    Request your free copy of the 'Human Immune Cytokines' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    Triple-Modality Therapy Maximizes Antitumor Immune Responses in a Mouse Model of Mesothelioma

    Investigators demonstrated a rationale to combine interleukin-15 superagonist and glucocorticoid-induced tumor necrosis factor receptor–related protein agonist with subablative radiotherapy in mesothelioma.
    [Science Translational Medicine]

    Abstract

    Developmental Partitioning of SYK and ZAP70 Prevents Autoimmunity and Cancer

    The authors identified aberrant ZAP70 expression as a common feature in a broad range of B cell malignancies. They validated SYK as the kinase that sets the thresholds for negative selection of autoreactive and premalignant clones.
    [Molecular Cell]

    AbstractGraphical Abstract

    Perivascular Macrophages Regulate Blood Flow Following Tissue Damage

    Using intravital microscopy of ischemic hind limb muscle in mice, and confocal microscopy of human tissues from amputated legs, scientists found that macrophages accumulated perivascularly in ischemic muscles, where they expressed high levels of iNOS.
    [Circulation Research]

    Abstract

    ARIH1 Signaling Promotes Anti-tumor Immunity by Targeting PD-L1 for Proteasomal Degradation

    Overexpression of ARIH1 suppressed tumor growth and promoted cytotoxic T cell activation in wild-type, but not in immunocompromised mice, highlighting the role of ARIH1 in anti-tumor immunity.
    [Nature Communications]

    Full Article

    Cell Barrier Function of Resident Peritoneal Macrophages in Post-Operative Adhesions

    The authors showed that resident F4/80HighCD206− peritoneal macrophages promptly accumulate on the lesion and form a ‘macrophage barrier’ to shield fibrin clots in place of the lost mesothelium in mice.
    [Nature Communications]

    Full Article

    Co-Delivery of IOX1 and Doxorubicin for Antibody-Independent Cancer Chemo-Immunotherapy

    The IOX1 and DOX combination greatly promoted T cell infiltration and activity and significantly reduced tumor immunosuppressive factors.
    [Nature Communications]

    Full Article

    Human KIT+ Myeloid Cells Facilitate Visceral Metastasis by Melanoma

    Using humanized mice that colonization of distant visceral organs with melanoma was dependent upon a human CD33+CD11b+CD117+ progenitor cell subset comprising.
    [Journal of Experimental Medicine]

    Full Article

    CCL2 Regulation of MST1-mTOR-STAT1 Signaling Axis Controls BCR Signaling and B-Cell Differentiation

    In SLE patients, decreased expression of CCL2 on mesenchymal stem cells prevented inhibition of B-cell proliferation, causing the characteristic autoimmune phenotype.
    [Cell Death & Differentiation]

    Abstract

    Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model

    Investigators used melanoma tumors arising from a genetically engineered mouse model to evaluate the efficacy of an anti-mouse PD-L1 antibody similar to the anti-human PD-L1 antibodies durvalumab and atezolizumab.
    [Molecular Cancer Research]

    Abstract

    Explore scientific resources for your immunology research at the STEMCELL Technologies immunology learning center
    REVIEWS

    Delivery Technologies to Engineer Natural Killer Cells for Cancer Immunotherapy

    Scientists provide an overview of the use of NK cells in cancer immunotherapy, their current status in clinical trials, as well as the design and implementation of delivery technologies.
    [Cancer Gene Therapy]

    Abstract

    INDUSTRY AND POLICY NEWS

    Monopteros Therapeutics Initiates Clinical Trial to Reprogram Regulatory T Cells in Solid Tumors

    Monopteros Therapeutics, Inc. announced that it has dosed the first patient in its Phase I/Ib dose escalation and cohort expansion clinical trial. The trial aims to evaluate the safety, efficacy, and pharmacology of MPT-0118 and to demonstrate the reprogramming of regulatory T cells.
    [Monopteros Therapeutics, Inc. (BusinessWire, Inc.)]

    Press Release

    FEATURED EVENT

    The American Association for Cancer Research (AACR) Annual Meeting 2021: Week 2

    May 17 – 21, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Technical Assistant – Mucosal Immunology

    Research Center for Molecular Medicine – Vienna, Austria

    Postdoctoral Position – T Follicular Helper Cell Differentiation

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Postdoctoral Research Fellow – Precision Vaccine Program

    Boston Children’s Hospital – Boston, Massachusetts, United States

    Postdoctoral Research Fellow – Innate Immunology

    Swiss Federal Institute of Technology in Lausanne – Lausanne, Switzerland

    Postdoctoral Position – Gene and Cell Therapy Development for Treatment of Primary Immune Deficiencies

    NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter